{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=69",
    "query": {
      "condition": "Skin and Connective Tissue Disease",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 15644,
    "total_pages": 1565,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:27:49.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00087776",
      "title": "Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Taxoprexin",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Regent, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 393,
      "start_date": "2002-12-06",
      "completion_date": "2007-10-27",
      "has_results": false,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "Norristown, Pennsylvania",
      "locations": [
        {
          "city": "Norristown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087776"
    },
    {
      "nct_id": "NCT02477332",
      "title": "Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "QGE031",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 382,
      "start_date": "2015-07-15",
      "completion_date": "2017-06-12",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477332"
    },
    {
      "nct_id": "NCT04134884",
      "title": "Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Positive Tumor"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kathy Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2020-04-01",
      "completion_date": "2024-03-14",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134884"
    },
    {
      "nct_id": "NCT00041652",
      "title": "Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colon Cancer",
        "Rectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Carcinoma",
        "Breast Cancer",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "hMN14 (labetuzumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2000-02",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2021-08-19",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041652"
    },
    {
      "nct_id": "NCT06133647",
      "title": "Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ductal Carcinoma in Situ",
        "Invasive Lobular Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "managing Male Breast Cancer Patients at Methodist Health System",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-05-04",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06133647"
    },
    {
      "nct_id": "NCT05797285",
      "title": "Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ulcer Healing",
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "human keratin graft",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ProgenaCare Global, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2023-02-28",
      "completion_date": "2023-12-20",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Frederick, Maryland • Salem, Virginia",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Salem",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797285"
    },
    {
      "nct_id": "NCT00634088",
      "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone + Lapatinib + Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2008-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-10",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634088"
    },
    {
      "nct_id": "NCT00686127",
      "title": "Symptom Management After Breast Cancer Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuropathic Pain",
        "Postmastectomy Pain"
      ],
      "interventions": [
        {
          "name": "Lidoderm patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2003-09",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-28",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686127"
    },
    {
      "nct_id": "NCT04205227",
      "title": "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Melanoma",
        "Ovary Cancer",
        "Pancreatic Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ENB003",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ENB Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-02-18",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205227"
    },
    {
      "nct_id": "NCT04895761",
      "title": "Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Letrozole 2.5mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        },
        {
          "name": "XRT 10Gy x2",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-10",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-19T04:27:49.285Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895761"
    }
  ]
}